State Of Play: Does UK See Value In Generics and Biosimilars?
Savings And Increased Access Overshadowed By Low Competition
Executive Summary
With 80% of medicines used by the UK’s National Health Service being off-patent drugs, the UK is nevertheless in need of a new economic framework to save waning competition due to low prices, delegates to a Westminster Health Forum conference heard from a Sandoz executive.